{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:20:38Z","timestamp":1789618838810,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Survival for patients with high\u2010risk neuroblastoma remains poor despite current\u2010era multimodality treatment that includes postconsolidation GD2\u2010directed immunotherapy. Given the promising responses in patients who receive dinutuximab\u2010based chemoimmunotherapy in the relapsed setting, the Children\u2019s Oncology Group ANBL19P1 study evaluated the feasibility of administering irinotecan, temozolomide, dinutuximab, and sargramostim after frontline consolidation with tandem autologous stem cell transplantation (ASCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with high\u2010risk neuroblastoma who received induction therapy followed by tandem ASCT and had no evidence of progressive disease (PD) were eligible. Treatment included five 28\u2010day cycles of temozolomide and irinotecan (days 1\u20135), dinutuximab (days 2\u20135), and sargramostim (days 6\u201312). Isotretinoin (days 8\u201321) was given during cycles 1\u20136. Therapy was deemed feasible if the 95% confidence interval placed on the percentage of patients that completed five cycles of chemoimmunotherapy without PD within 30 weeks contained 75% in the absence of excessive toxicity. Event\u2010free survival and overall survival were determined from the time of enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty eligible patients enrolled, and 35 (87.5%; 95% confidence interval, 73.9%\u201394.5%) completed five cycles without PD within 30 weeks, meeting the feasibility threshold. No unacceptable toxicities occurred on protocol therapy, including no toxic deaths. Five patients discontinued therapy early because of physician determination (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02), patient\/parent refusal of further therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02), and PD (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01). The 2\u2010year event\u2010free and overall survival rates were 82.5%\u00a0\u00b1\u00a06.1% and 92.5%\u00a0\u00b1\u00a04.2%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The administration of chemoimmunotherapy in the postconsolidation setting after tandem ASCT is feasible and tolerable. Future studies will be needed to define the population most likely to benefit from this augmented postconsolidation therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70165","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:25:15Z","timestamp":1768292715000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A pilot study of chemoimmunotherapy in the postconsolidation setting for high\u2010risk neuroblastoma (ANBL19P1): A report from the Children\u2019s Oncology Group"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9658-3156","authenticated-orcid":false,"given":"Ami V.","family":"Desai","sequence":"first","affiliation":[{"name":"Section of Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, University of Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Naranjo","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group Statistics and Data Center University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"LaBarre","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group Statistics and Data Center University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Chen","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group Statistics and Data Center University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Goldsmith","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center at Children\u2019s Healthcare of Atlanta and Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan P.","family":"Granger","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"States","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean G.","family":"Green","sequence":"additional","affiliation":[{"name":"Lucile Packard Children\u2019s Hospital Stanford  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariel","family":"Trunzo","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-738X","authenticated-orcid":false,"given":"Steven G.","family":"DuBois","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber\/Boston Children\u2019s Cancer and Blood Disorders Center Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Bagatell","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Park","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Marachelian","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201020\u20103909"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02478"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11642"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30355\u20108"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.10508"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.6876"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0177"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26636"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201019\u20101452"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01375"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.10003"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184609"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30572"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34263"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7051"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1249929"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2018.10.010"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28031"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2021.12.007"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf008"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196223"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2024.103199"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201017\u20101767"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102022\u2010006530"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1235108"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100161"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:45:02Z","timestamp":1772995502000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,15]]}},"alternative-id":["10.1002\/cncr.70165"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70165","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"2025-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70165"}}